Trial Profile
Effectiveness of afatinib administered at different doses to patients with EGFR-mutated lung adenocarcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 19 Sep 2018 New trial record
- 07 Sep 2018 Results published in the European Journal of Cancer